Related Experiment Video

Updated: Jul 14, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN

Igor Vivanco1, Nicolaos Palaskas, Chris Tran

  • 1Molecular Biology Institute, University of California at Los Angeles, Los Angeles, CA 90095, USA.

Cancer Cell
|June 15, 2007
PubMed

Insights

Loss of PTEN (phosphatase and tensin homolog) activates AKT, but not all oncogenic phenotypes. This study identifies JNK activation as another key pathway regulated by PTEN loss, crucial in prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • PTEN loss is a common driver in many cancers.
  • While AKT activation is a known consequence of PTEN loss, it doesn't fully explain all associated oncogenic phenotypes.
  • The role of other signaling pathways in PTEN-deficient cancers remains incompletely understood.

Purpose of the Study:

  • To identify additional PTEN-regulated signaling pathways beyond AKT.
  • To investigate the functional significance of these pathways in PTEN-deficient cancers.
  • To explore the therapeutic implications of targeting these pathways.

Main Methods:

  • Gene Set Enrichment Analysis (GSEA) was employed to identify PTEN-regulated pathways.
  • Genetic studies were conducted to elucidate the relationship between PTEN, AKT, and JNK signaling.
  • Analysis of human prostate cancer samples was performed to correlate pathway activation.

Main Results:

  • GSEA identified JNK activation as a pathway associated with PTEN loss.
  • PTEN-null cells exhibit increased JNK activity, functioning independently of AKT.
  • PTEN deficiency sensitizes cells to JNK inhibition, and PI3K feedback regulation is impaired.
  • Activated AKT and JNK are correlated in human prostate cancer.

Conclusions:

  • JNK signaling plays a parallel and independent role to AKT in PTEN-deficient cancers.
  • JNK inhibition represents a potential therapeutic strategy for PTEN-driven cancers.
  • GSEA is a valuable tool for discovering functional pathways in genetically defined systems.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...